IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v13y2015i2p233-242.html

Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism

Author

Listed:
  • C. Rubio-Terrés
  • J. Soria
  • P. Morange
  • J. Souto
  • P. Suchon
  • J. Mateo
  • N. Saut
  • D. Rubio-Rodríguez

  • J. Sala
  • A. Gracia
  • S. Pich
  • E. Salas

Abstract

According to the economic model, Thrombo inCode ® is the dominant option in assessing the risk of VTE, compared with the standard method currently used. Copyright The Author(s) 2015

Suggested Citation

  • C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas, 2015. "Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 233-242, April.
    • Handle: RePEc:spr:aphecp:v:13:y:2015:i:2:p:233-242
    DOI: 10.1007/s40258-015-0153-x
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40258-015-0153-x
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40258-015-0153-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    2. John Brazier & Jennifer Roberts & Aki Tsuchiya & Jan Busschbach, 2004. "A comparison of the EQ‐5D and SF‐6D across seven patient groups," Health Economics, John Wiley & Sons, Ltd., vol. 13(9), pages 873-884, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ifigeneia Mavranezouli & Joran Lokkerbol, 2017. "A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder," PharmacoEconomics, Springer, vol. 35(3), pages 271-296, March.
    2. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    3. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 261-271, July.
    4. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    5. Richard Grieve & Marina Grishchenko & John Cairns, 2009. "SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 15-23, February.
    6. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    7. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.
    8. Yifan Li & Vivien Kin Yi Chan & Mark Jit & Franco Wing Tak Cheng & Hei Hang Edmund Yiu & David Makram Bishai & Dawn Craig & Esther Wai Yin Chan & Sandra Sau Man Chan & Xue Li, 2026. "Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study," PLOS Medicine, Public Library of Science, vol. 23(4), pages 1-1, April.
    9. Michael S. Willis & Andreas Nilsson & Cheryl A. Neslusan, 2025. "A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care," PharmacoEconomics, Springer, vol. 43(6), pages 601-616, June.
    10. Julie A. Campbell & Glen J. Henson & Valery Fuh Ngwa & Hasnat Ahmad & Bruce V. Taylor & Ingrid Mei & Andrew J. Palmer, 2025. "Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications," PharmacoEconomics, Springer, vol. 43(2), pages 223-239, February.
    11. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    12. Risha Gidwani & Louise B. Russell, 2020. "Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1277-1277, November.
    13. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
    14. Elizaveta Sopina & Jan Sørensen, 2018. "Decision modelling of non-pharmacological interventions for individuals with dementia: a systematic review of methodologies," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    15. Aureliano Paolo Finch & John Edward Brazier & Clara Mukuria, 2018. "What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 557-570, May.
    16. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    17. Matthew Franklin & Sebastian Hinde & Rachael Maree Hunter & Gerry Richardson & William Whittaker, 2024. "Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 435-445, July.
    18. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    19. SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    20. Xinyue Dong & Xiaoning He & Jing Wu, 2022. "Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting," PharmacoEconomics, Springer, vol. 40(12), pages 1187-1205, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:13:y:2015:i:2:p:233-242. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.